Forget This Biotech Stock’s Rally Signals Fresh Jump
NovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
Market cap weighting tends to allocate more to larger firms, influencing risk and return. This intro outlines the rationale and implications.
28,489 articlesNovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
BlackRock’s new staked Ethereum ETF opened with notable volume and assets topping $100 million, signaling growing app...
Nvidia sits at a potential turning point, guided by a history of cycles tied to AI and data centers. This article unf...
Anchorage Digital announces a historic custody milestone, expanding regulated access to Tron assets for institutional...
The Senate Banking Committee is set to mark up the CLARITY Act on May 14, moving a stalled crypto market-structure bi...
JPMorgan researchers warn that ether and other altcoins could keep lagging Bitcoin without clearer growth in on-chain...
A deal of this size reshapes risk, rewards, and portfolio strategy. Here is the thing investors should know and pract...
A prominent AI founder challenges the notion that automation alone boosts margins, revealing a doubled headcount desp...
As a new Fed chair, chair kevin warsh will confront two high-stakes tests in just 100 days. One test centers on polit...
ConocoPhillips faces a clash between a wave of Buy ratings and a cautious price target, as crude markets rebound and ...
NovaCore Technologies enters the second half of 2026 with a multi-year backlog, AI revenue momentum, and cloud growth...
XRP has climbed over 9% in the past week and now trades near $1.15 after a brief dip to $1.01. Analysts say the token...